Clinical effect of epidermal growth factor receptor-targeted agents in treatment of advanced pancreatic cancer: A Meta-analysis
10.3969/j.issn.1001-5256.2020.05.029
- VernacularTitle:表皮生长因子受体靶向药物对进展期胰腺癌治疗作用的Meta分析
- Author:
Zidong ZHOU
1
;
Renli LI
;
Kai CHEN
Author Information
1. Logistics University of Chinese People’s Armed Police Forces, Tianjin 300309, China
- Publication Type:Research Article
- Keywords:
pancreatic neoplasms;
receptor, epidermal growth factor;
therapeutics;
Meta-analysis as topic
- From:
Journal of Clinical Hepatology
2020;36(5):1097-1103
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo systematically evaluate the clinical effect of epidermal growth factor receptor (EGFR)-targeted agents in the treatment of advanced pancreatic cancer. MethodsEMbase, PubMed, Cochrane Library, Clinical Trials, CNKI, Wanfang Data, and VIP were searched for randomized controlled trials (RCTs) of EGFR-targeted therapies for advanced pancreatic cancer. Eligible RCTs were screened out based on quality and related criteria, and RevMan 5.3 and STATA 12.0 were used to perform the meta-analysis. ResultsA total of 8 RCTs were included, with 2382 patients in total. The results of the meta-analysis showed that compared with the control group, the experimental group had no increases in overall survival time (hazard ratio ［HR］=0.86, 95% confidence interval ［CI］: 0.74-1.02, P＞0.05) and objective response rate (risk ratio ［RR］=1.00, 95%CI: 0.76-1.32, P＞0.05), but had significant increases in progression-free survival time (HR=0.78, 95%CI: 0.62-0.98, P＜0.05) and disease control rate (RR=1.22, 95%CI: 1.04-1.43, P＜0.05). The subgroup analysis showed that after the source of heterogeneity was identified and the studies with high heterogeneity were excluded, the experimental group had a significant increase in overall survival time (HR=0.85, 95%CI: 0.77-0.94, P＜0.05), and the patients with rash appeared to be more sensitive to the therapies (HR=0.70, 95%CI: 0.54-0.92, P＜0.05). ConclusionFor patients with advanced pancreatic cancer, EGFR-targeted therapies can effectively prolong overall survival time and improve quality of life.
